NCT06027229View on ClinicalTrials.gov

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

April 24, 2024

Study Completion Date

September 9, 2024

Conditions
ImmunosuppressionCOVID-19
Interventions
BIOLOGICAL

NVX-CoV2372

Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5

Trial Locations (1)

53792

UW School of Medicine and Public Health, Madison

Sponsors

Collaborators (1)

Novavax
All Listed Sponsors
collaborator

Novavax

INDUSTRY

lead

University of Wisconsin, Madison

OTHER